B.Thorens is the leader of an IMI project on diabetes, a collaboration between 15 research groups from different european countries and 8 pharmaceutical industries.

“Innovative Medicines Initiative”  is a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The aim of IMI is to to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector.

2 other swiss groups participate in this project on diabetes, one from the UNIGE and one from the SIB (I.Xenarios).